SSII Achieves World's First Intercontinental Robotic Cardiac Telesurgery

By Greg Peters • Tuesday, July 22 10:26 • Permanent Link

SS Innovations International, Inc. (NASDAQ: SSII) has made a significant breakthrough in the field of robotic surgery. The company's chairman of the board and chief executive officer, Dr. Sudhir Srivastava, M.D., successfully completed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025. This achievement was made possible by utilizing the company’s SSI Mantra 3 surgical robotic system to perform a robotic atrial septal defect closure remotely from the Institute of Research Against Digestive Cancer (“IRCAD”) in Strasbourg, France to the operating room at the Sri Aurobindo Institute of Medical Sciences (“SAIMS”) in Indore, India, at an unprecedented transmission distance of more than 4,000 miles.

The live telesurgery was moderated by robotic cardiac surgeon Dr. Husam H. Balkhy, M.D., and the team successfully completed the surgery without any technical issues and with flawless precision, seamless robotic control, and imperceptible latency, showcasing the robustness of the SSI Mantra 3 and its revolutionary telesurgery architecture.

This historic achievement not only demonstrates the advanced capabilities of the SSI Mantra 3 surgical robotic system but also further paves the way for redefining and democratizing global delivery of complex cardiac care, especially in regions with limited access to surgical expertise.

To date, 35 telesurgeries, including 10 cardiac procedures, and a total of 250 cardiac procedures have been successfully completed utilizing the SSI Mantra surgical robotic system. Additionally, over 5,000 multi-specialty surgeries have been successfully carried out with the SSI Mantra system without any device-related adverse events.

Furthermore, SS Innovations is the only surgical robotic company to have received regulatory approval from the Central Drugs Standard Control Organization (“CDSCO”), India’s equivalent of the U.S. Food and Drug Administration, for both teleproctoring and telesurgery. This approval underscores the company’s commitment to advancing the field of robotic surgery and expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.

This achievement not only marks a significant milestone for SS Innovations but also signifies a major advancement in the field of robotic surgery, particularly in the realm of complex cardiac procedures. Today the company's shares have moved 5.93% to a price of $8.40. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.